Literature DB >> 25773547

Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysis.

Mark Sculpher1.   

Abstract

Mesh:

Year:  2015        PMID: 25773547     DOI: 10.1016/j.jval.2015.02.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  4 in total

1.  Cost-effectiveness of intravenous acetaminophen and ketorolac in adolescents undergoing idiopathic scoliosis surgery.

Authors:  Vidya Chidambaran; Rajeev Subramanyam; Lili Ding; Senthilkumar Sadhasivam; Kristie Geisler; Bobbie Stubbeman; Peter Sturm; Viral Jain; Mark H Eckman
Journal:  Paediatr Anaesth       Date:  2018-01-29       Impact factor: 2.556

2.  Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation.

Authors:  Padraig Dixon; George Davey Smith; Stephanie von Hinke; Neil M Davies; William Hollingworth
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

3.  Predicting Therapy Success and Costs for Personalized Treatment Recommendations Using Baseline Characteristics: Data-Driven Analysis.

Authors:  Vincent Bremer; Dennis Becker; Spyros Kolovos; Burkhardt Funk; Ward van Breda; Mark Hoogendoorn; Heleen Riper
Journal:  J Med Internet Res       Date:  2018-08-21       Impact factor: 5.428

4.  Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.

Authors:  M Abdel-Fattah; C Chapple; K Guerrero; S Dixon; N Cotterill; K Ward; H Hashim; A Monga; K Brown; M J Drake; A Gammie; A Mostafa; U K Bladder Health; S Breeman; D Cooper; G MacLennan; J Norrie
Journal:  Trials       Date:  2021-10-26       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.